Alaunos Therapeutics, Inc.

TCRT · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$4,679-$35,140-$37,730-$78,751
Dep. & Amort.$2$2,315$2,759$2,597
Deferred Tax$0$0$0$0
Stock-Based Comp.$435$2,800$3,528$10,774
Change in WC-$729-$6,254$870$3,141
Other Non-Cash$0$6,137$1,341$771
Operating Cash Flow-$4,971-$30,142-$29,232-$61,468
Investing Activities
PP&E Inv.$0-$197-$216-$3,323
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$1,543$23$0
Investing Cash Flow$0$1,346-$193-$3,323
Financing Activities
Debt Repay.$0-$18,105-$8,333$25,000
Stock Issued$0$92$14,724$0
Stock Repurch.$0$0-$45$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0-$125$21$776
Financing Cash Flow$0-$18,138$6,367$25,776
Forex Effect$0$0$0$0
Net Chg. in Cash-$4,971-$46,934-$23,058-$39,015
Supplemental Information
Beg. Cash$6,062$52,996$76,054$115,069
End Cash$1,091$6,062$52,996$76,054
Free Cash Flow-$4,971-$30,339-$29,448-$64,791
Alaunos Therapeutics, Inc. (TCRT) Financial Statements & Key Stats | AlphaPilot